Skip to main content
Category

Research

Targeted Oncology
ResearchTreatments

Lower-Dose Trastuzumab Deruxtecan Shows Favorable Efficacy in HER2-Mutated NSCLC

*September 2022* Trastuzumab deruxtecan (Enhertu) demonstrated clinically meaningful benefit and a favorable safety profile at the lower of 2 dose levels in patients with HER2-mutated non–small cell lung cancer (NSCLC), according to interim results of the DESTINY-Lung02 trial (NCT04644237) presented at the 2022 European Society for Medical Oncology (ESMO) Congress.1…
laurabbook@gmail.com
October 30, 2022
ResearchTreatments

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

*June 2022* Highlights: Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial. Although the 12-month PFS probability was 70.2%, which did not meet the primary end point, the median PFS was 21.3 months suggesting the promising efficacy of this alternative…
laurabbook@gmail.com
October 30, 2022
Research to Practice
ResearchTreatments

Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

*September 2022* Lung cancer specialist Lecia V Sequist, MD, MPH discusses the current and future management of EGFR NSCLC with host Dr. Neal Love. This informative presentation is available in the following formats: video, audio, and powerpoint slides.  Listen to the audio/read transcription here.  Watch the video/download slides here. Please…
laurabbook@gmail.com
October 30, 2022
OncLive
ResearchTreatments

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

*August 2022* Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses additional studies investigating the use of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) in EGFR-mutated non–small cell lung cancer (NSCLC).…
laurabbook@gmail.com
September 25, 2022
IASLC
ResearchTreatments

Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

*August 2022* From WCLC Abstract presented by Dr. Jie Huang Introduction: Small cell lung cancer (SCLC) transformation remains one of the unsettled resistant mechanisms for lung adenocarcinoma (LUAD), of which co-occurring TP53 and RB1 mutations defined a subgroup of patients with increased risk of SCLC transformation. Our study aimed to…
laurabbook@gmail.com
September 25, 2022